RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

HOUSTON -- Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor. A pooled ...

SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...

BUFFALO, NY- October 11, 2024 – A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Transplant or no transplant for TP53 mutated AML.” As highlighted in this ...

Ivosidenib plus azacitidine significantly prolongs median overall survival in patients with IDH1-mutated acute myeloid leukemia (AML), with a median overall survival of 29.3 months versus 7.9 months ...

SELLAS Life Sciences Group, Inc. has announced promising preclinical results for SLS009, a selective CDK9 inhibitor, in treating TP53 mutated Acute Myeloid Leukemia (AML) cells, which typically have ...

1.5-year clinical outcomes in patients with triple-mutated AML who were positive and negative for MRD before allo-HSCT. This paper explores the clinical outcomes of allogeneic hematopoietic stem cell ...

A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, "Transplant or no transplant for TP53 mutated AML." As highlighted in this editorial, TP53 mutations (mut) occur ...

CEO Dr Daniel Tillett talked with Proactive about the company’s launch of two new clinical programs for its lead asset, RC220 ...